DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20214097

Role of clobetasol propionate 0.025% topical therapy in various dermatoses

Vishalakshi Vishwanath, Arvind Chaudhary, Ankit Agarwal, Bhukya Jyothi, C. Chitharanjan, Lokesh Rao Bangady Killur, M. M. Bhat, Nilendu Sarma, Prashant K. Palwade, Pravin Banodkar

Abstract


The anti-inflammatory and vasoconstrictive properties of topical corticosteroids (TCs) contribute in providing therapeutic benefits in several skin conditions, including atopic eczema, localized vitiligo, psoriasis, and chronic hand eczema. Clobetasol propionate (CP) is the most common topical agent used for psoriasis management and demonstrates an efficacy superior to other TCs. A new CP 0.025% cream formulation has demonstrated hypoallergenic effects due to the absence of known contact allergens, such as propylene glycol, short-chain alcohols, and sorbitol-based emulsifiers. Lower CP serum levels and less hypothalamic–pituitary–adrenal axis suppression with CP 0.025% cream formulation than with CP 0.05% ensure better safety. The present case series discusses the clinical experience of using CP 0.025% cream in various dermatological conditions.


Keywords


Clobetasol propionate 0.025%, Plaque psoriasis, Psoriasis, Topical corticosteroid

Full Text:

PDF

References


Mehta AB, Nadkarni NJ, Patil SP. Topical corticosteroids in dermatology. Indian J Dermatol Venereol Leprol. 2016;82:371-8.

Das A, Panda S. Use of topical corticosteroids in dermatology: An evidence-based approach. Indian J Dermatol. 2017;62(3):237-50.

Del Rosso JQ. Topical corticosteroid therapy for psoriasis—a review of clobetasol propionate 0.025% cream and the clinical relevance of penetration modification. J Clin Aesthet Dermatol. 2020;13(2):22-9.

Uva L, Miguel D, Pinheiro C, Antunes J, Cruz D, Ferreira J, Filipe P. Mechanisms of action of topical corticosteroids in psoriasis. Int J Endocrinol. 2012;561018.

Zampetti A, Feliciani C, Tulli A, Amerio P. Pharmacotherapy of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses focus on clobetasol propionate. Clin Med Insights Ther. 2010;2:523-37.

Draelos ZD, Fowler JF, Cornelison R. A randomized, parallel group, open label, multicenter study to assess the potential for adrenal suppression and systemic drug absorption following multiple dosing with clobetasol propionate cream (Impoyz™), 0.025% versus clobetasol propionate (Temovate®). J Cutan Med Surg. 2018;2(6):410-20.